Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 15:110:129875.
doi: 10.1016/j.bmcl.2024.129875. Epub 2024 Jul 2.

Semisynthetic derivatives of the fungal metabolite eupenifeldin via targeting the tropolone hydroxy groups

Affiliations

Semisynthetic derivatives of the fungal metabolite eupenifeldin via targeting the tropolone hydroxy groups

Zeinab Y Al Subeh et al. Bioorg Med Chem Lett. .

Abstract

Eupenifeldin (1) is a fungal secondary metabolite possessing bis-tropolone moieties that demonstrates nanomolar cytotoxic activity against a number of cancer cell types. As a potential anticancer lead, this meroterpenoid was used to access 29 semisynthetic analogues via functionalization of the reactive hydroxy groups of the bis-tropolones. A series of ester (2-6), carbonate (7-8), sulfonate (9-16), carbamate (17-20), and ether (21-30) analogues of 1 were generated via 22 reactions. Most of these compounds were disubstituted, produced via functionalization of both of the tropolonic hydroxy moieties, although three mono-functionalized analogues (6, 8, and 24) and one tri-functionalized analogue (3) were also obtained. The cytotoxic activities of 1-30 were evaluated against human melanoma and ovarian cancer cell lines (i.e., MDA-MB-435 and OVCAR3, respectively). Ester and carbonate analogues of 1 (i.e., 2-8) maintained cytotoxicity at the nanomolar level, and the greatest improvement in aqueous solubility came from the monosuccinate analogue (6), which was acylated on the secondary hydroxy at the 11 position.

Keywords: Bis-tropolone; Eupenifeldin; Fungal metabolites; Meroterpenoids; Semisynthetic analogues.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Nicholas Oberlies reports a relationship with Mycosynthetix Inc that includes: board membership. Nicholas Oberlies reports a relationship with Clue Genetics Inc that includes: board membership. Nicholas Oberlies reports a relationship with Ionic Pharmaceuticals LLC that includes: board membership. Cedric Pearce reports a relationship with Clue Genetics Inc that includes: board membership. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

References

    1. Kinghorn AD, Chin Y-W, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Discov Devel. 2009;12(2): 189–196. - PMC - PubMed
    1. Aldrich LN, Burdette JE, Carcache de Blanco E, et al. Discovery of anticancer agents of diverse natural origin. J Nat Prod. 2022;85(3): 702–719. 10.1021/acs.jnatprod.2c00036. - DOI - PMC - PubMed
    1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3): 770–803. 10.1021/acs.jnatprod.9b01285. - DOI - PubMed
    1. Guo Z The modification of natural products for medical use. Acta Pharm Sin B. 2017;7(2): 119–136. 10.1016/j.apsb.2016.06.003. - DOI - PMC - PubMed
    1. Majhi S, Das D. Chemical derivatization of natural products: semisynthesis and pharmacological aspects- A decade update. Tetrahedron. 2021;78: 131801. 10.1016/j.tet.2020.131801. - DOI

MeSH terms

LinkOut - more resources